Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by gebremeskelon Aug 28, 2024 3:19pm
178 Views
Post# 36199940

The position of PMX within Vantive

The position of PMX within VantiveChristopher Seto Quote (Feb. 2024):

"...With Vantive and since they’ve announced the Vantive spin-off, we feel that Spectral has been positioned as a key strategic priority. We’ve seen this in Baxter’s investor presentations where both EA and PMX are key featured product launches for Vantive.
 
Also, when you look at the portfolio of products within Vantive, PMX definitely has significantly higher growth potential and significantly enhanced gross margins relative to their other products. And that’s the nature of our PMX product. It’s unique. It’s not a commodity. There’s no alternatives. And if we get this right, PMX will be the standard of care for ESS and the US ICU population. And I think these are the characteristics that really excite Vantive and ultimately drive the enthusiasm and support that we have witnessed to date. So overall, we feel we’re very important in — well — we feel we were very important in the legacy Baxter world. Our association with Vantive feels like that importance is certainly amplified, if you will."

https://stockspinoffinvesting.com/spin-offs/baxter-renal-spinoff-notes/
<< Previous
Bullboard Posts
Next >>